Cutaneous CpG adjuvant conditioning to enhance vaccine responses

Adjuvant activity of the Toll receptor 9 agonist CpG 1826 was compared when given subcutaneously (s.c.) together with ovalbumin (s.c.[CpG + Ova]), or when given by either s.c. or intradermally (i.d.) routes two days prior to s.c. ovalbumin.

Citation:
Carlow DA, Lai JCY, Kollmann TR, Sadarangani M, Dutz JP. Cutaneous CpG adjuvant conditioning to enhance vaccine responses. Vaccine. 2022.

Keywords:
CD8+ T cells; Conditioning; CpG; Innate immunity; Intradermal immunization; Skin

Abstract:
Adjuvant activity of the Toll receptor 9 agonist CpG 1826 was compared when given subcutaneously (s.c.) together with ovalbumin (s.c.[CpG + Ova]), or when given by either s.c. or intradermally (i.d.) routes two days prior to s.c. ovalbumin.